PRINCETON, N.J., Feb. 23 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (Nasdaq: DSCI), a specialty medical device and pharmaceutical company focused on advanced wound care, today announced that it has successfully negotiated an additional three years on its current BIOGUARD™ licensing agreement with Quick-Med Technologies, Inc. (OTC Bulletin Board: QMDT). This contract extension results in a potential 8-year term for Derma Sciences' newest product entrant into the $14 billion global advanced wound care market. Additionally, Derma will now have expanded exclusivity to include the majority of remaining gauze-based products, including non-woven gauze dressings.
